{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:15Z","timestamp":1791983655937,"version":"4.4.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":76,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13311-021-01082-x","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T14:08:42Z","timestamp":1631714922000},"page":"1535-1547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome"],"prefix":"10.1016","volume":"18","author":[{"given":"Nycole A.","family":"Copping","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"McTighe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle D.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9357-5476","authenticated-orcid":false,"given":"Jill L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1007\/s13311-021-01082-x_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/GIM.0b013e3181def138","article-title":"Clinical and genetic aspects of Angelman syndrome","volume":"12","author":"Williams","year":"2010","journal-title":"Genet Med."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s13311-015-0361-y","article-title":"Angelman Syndrome","volume":"12","author":"Margolis","year":"2015","journal-title":"Neurotherapeutics."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1891\/0730-0832.36.3.142","article-title":"Angelman Syndrome: Identification and Management","volume":"36","author":"Bonello","year":"2017","journal-title":"Neonatal Netw."},{"issue":"5","key":"10.1007\/s13311-021-01082-x_bib4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajmg.a.31074","article-title":"Angelman syndrome 2005: updated consensus for diagnostic criteria","volume":"140","author":"Williams","year":"2006","journal-title":"Am J Med Genet A."},{"issue":"11","key":"10.1007\/s13311-021-01082-x_bib5","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1111\/j.1528-1167.2009.02108.x","article-title":"Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options","volume":"50","author":"Thibert","year":"2009","journal-title":"Epilepsia."},{"issue":"5","key":"10.1007\/s13311-021-01082-x_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.braindev.2004.01.009","article-title":"Evolution of seizures and electroencephalographical findings in 23 cases of deletion type Angelman syndrome","volume":"27","author":"Uemura","year":"2005","journal-title":"Brain Dev."},{"key":"10.1007\/s13311-021-01082-x_bib7","doi-asserted-by":"crossref","unstructured":"Khan N, Cabo R, Tan WH, Tayag R, Bird LM. Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman Syndrome Natural History Study. Mol Genet Genomic Med. 2019;7(7):e00734.","DOI":"10.1002\/mgg3.734"},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng0197-70","article-title":"UBE3A\/E6-AP mutations cause Angelman syndrome","volume":"15","author":"Kishino","year":"1997","journal-title":"Nat Genet."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ng0197-74","article-title":"De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome","volume":"15","author":"Matsuura","year":"1997","journal-title":"Nat Genet."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/ng0792-291","article-title":"Maternal but not paternal transmission of 15q11-13-linked nondeletion Angelman syndrome leads to phenotypic expression","volume":"1","author":"Wagstaff","year":"1992","journal-title":"Nat Genet."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1101\/gr.7.4.368","article-title":"The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region","volume":"7","author":"Sutcliffe","year":"1997","journal-title":"Genome Res."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng0997-75","article-title":"Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons","volume":"17","author":"Albrecht","year":"1997","journal-title":"Nat Genet."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ng0997-12","article-title":"Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain","volume":"17","author":"Vu","year":"1997","journal-title":"Nat Genet."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ng0997-14","article-title":"The Angelman syndrome candidate gene, UBE3A\/E6-AP, is imprinted in brain","volume":"17","author":"Rougeulle","year":"1997","journal-title":"Nat Genet."},{"issue":"8","key":"10.1007\/s13311-021-01082-x_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/hmg\/ddg106","article-title":"Neurons but not glial cells show reciprocal imprinting of sense and antisense transcripts of Ube3a","volume":"12","author":"Yamasaki","year":"2003","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1006\/geno.2001.6543","article-title":"The Prader-Willi syndrome imprinting center activates the paternally expressed murine Ube3a antisense transcript but represses paternal Ube3a","volume":"73","author":"Chamberlain","year":"2001","journal-title":"Genomics."},{"issue":"23","key":"10.1007\/s13311-021-01082-x_bib17","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1093\/hmg\/10.23.2687","article-title":"The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar RNA species and as an antisense RNA for UBE3A","volume":"10","author":"Runte","year":"2001","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/hmg\/8.1.129","article-title":"The spectrum of mutations in UBE3A causing Angelman syndrome","volume":"8","author":"Fang","year":"1999","journal-title":"Hum Mol Genet."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib19","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/humu.22687","article-title":"Mutation Update for UBE3A variants in Angelman syndrome","volume":"35","author":"Sadikovic","year":"2014","journal-title":"Hum Mutat."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/302473","article-title":"Genetics of Angelman syndrome","volume":"65","author":"Jiang","year":"1999","journal-title":"Am J Hum Genet."},{"issue":"7380","key":"10.1007\/s13311-021-01082-x_bib21","first-page":"150","article-title":"Angelman syndrome: Drugs to awaken a paternal gene","volume":"481","author":"Beaudet","year":"2011","journal-title":"Nature."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrneurol.2012.2","article-title":"Neurodevelopmental disorders: Unsilencing dormant Ube3a\u2013hope for Angelman syndrome?","volume":"8","author":"Malpass","year":"2012","journal-title":"Nat Rev Neurol."},{"issue":"18","key":"10.1007\/s13311-021-01082-x_bib23","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/hmg\/ddl225","article-title":"Expression of the Rho-GEF Pbl\/ECT2 is regulated by the UBE3A E3 ubiquitin ligase","volume":"15","author":"Reiter","year":"2006","journal-title":"Hum Mol Genet."},{"issue":"34","key":"10.1007\/s13311-021-01082-x_bib24","doi-asserted-by":"crossref","first-page":"12399","DOI":"10.1073\/pnas.0805291105","article-title":"A Drosophila model for Angelman syndrome","volume":"105","author":"Wu","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib25","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","article-title":"Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation","volume":"21","author":"Jiang","year":"1998","journal-title":"Neuron."},{"key":"10.1007\/s13311-021-01082-x_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fncel.2017.00062","article-title":"Early Origin and Evolution of the Angelman Syndrome Ubiquitin Ligase Gene Ube3a","volume":"11","author":"Sato","year":"2017","journal-title":"Front Cell Neurosci."},{"key":"10.1007\/s13311-021-01082-x_bib27","doi-asserted-by":"crossref","unstructured":"Jana NR. Understanding the pathogenesis of Angelman syndrome through animal models. Neural Plast. 2012;2012:710943.","DOI":"10.1155\/2012\/710943"},{"key":"10.1007\/s13311-021-01082-x_bib28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-3-319-53889-1_23","article-title":"Stem Cell Technology for (Epi)genetic Brain Disorders","volume":"978","author":"Riemens","year":"2017","journal-title":"Adv Exp Med Biol."},{"issue":"R1","key":"10.1007\/s13311-021-01082-x_bib29","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1093\/hmg\/ddv476","article-title":"Gene-targeting pharmaceuticals for single-gene disorders","volume":"25","author":"Beaudet","year":"2016","journal-title":"Hum Mol Genet."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib30","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ajmg.c.31536","article-title":"Angelman syndrome: Current and emerging therapies in 2016","volume":"172","author":"Tan","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"10.1007\/s13311-021-01082-x_bib31","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1471-2202-15-76","article-title":"The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders","volume":"15","author":"Bailus","year":"2014","journal-title":"BMC Neurosci."},{"issue":"13","key":"10.1007\/s13311-021-01082-x_bib32","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1002\/j.1460-2075.1991.tb04990.x","article-title":"A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18","volume":"10","author":"Huibregtse","year":"1991","journal-title":"EMBO J."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1006\/geno.1997.4617","article-title":"The human E6-AP gene (UBE3A) encodes three potential protein isoforms generated by differential splicing","volume":"41","author":"Yamamoto","year":"1997","journal-title":"Genomics."},{"issue":"3\u20135","key":"10.1007\/s13311-021-01082-x_bib34","first-page":"100","article-title":"Molecular and Clinical Aspects of Angelman Syndrome","volume":"2","author":"Dagli","year":"2012","journal-title":"Mol Syndromol."},{"issue":"6509","key":"10.1007\/s13311-021-01082-x_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/373081a0","article-title":"Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade","volume":"373","author":"Scheffner","year":"1995","journal-title":"Nature."},{"issue":"5443","key":"10.1007\/s13311-021-01082-x_bib36","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.286.5443.1321","article-title":"Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2\u2013E3 enzyme cascade","volume":"286","author":"Huang","year":"1999","journal-title":"Science."},{"key":"10.1007\/s13311-021-01082-x_bib37","doi-asserted-by":"crossref","unstructured":"Tomaic V, Banks L. Angelman syndrome-associated ubiquitin ligase UBE3A\/E6AP mutants interfere with the proteolytic activity of the proteasome. Cell Death Dis. 2015;6:e1625.","DOI":"10.1038\/cddis.2014.572"},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1128\/MCB.19.2.1182","article-title":"The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily","volume":"19","author":"Nawaz","year":"1999","journal-title":"Mol Cell Biol."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s12035-013-8563-y","article-title":"E6AP in the brain: one protein, dual function, multiple diseases","volume":"49","author":"El Hokayem","year":"2014","journal-title":"Mol Neurobiol."},{"issue":"39","key":"10.1007\/s13311-021-01082-x_bib40","doi-asserted-by":"crossref","first-page":"41208","DOI":"10.1074\/jbc.M401302200","article-title":"Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein","volume":"279","author":"Cooper","year":"2004","journal-title":"J Biol Chem."},{"issue":"15","key":"10.1007\/s13311-021-01082-x_bib41","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/MCB.00201-12","article-title":"Identification and proteomic analysis of distinct UBE3A\/E6AP protein complexes","volume":"32","author":"Martinez-Noel","year":"2012","journal-title":"Mol Cell Biol."},{"issue":"7","key":"10.1007\/s13311-021-01082-x_bib42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jmb.2018.01.021","article-title":"Network Analysis of UBE3A\/E6AP-Associated Proteins Provides Connections to Several Distinct Cellular Processes","volume":"430","author":"Martinez-Noel","year":"2018","journal-title":"J Mol Biol."},{"issue":"11","key":"10.1007\/s13311-021-01082-x_bib43","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/hmg\/ddy103","article-title":"Quantitative proteomics reveals neuronal ubiquitination of Rngo\/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome","volume":"27","author":"Ramirez","year":"2018","journal-title":"Hum Mol Genet."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1432-1327.1998.2540643.x","article-title":"The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate","volume":"254","author":"Nuber","year":"1998","journal-title":"Eur J Biochem."},{"issue":"11","key":"10.1007\/s13311-021-01082-x_bib45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1080\/15592294.2017.1376151","article-title":"UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons","volume":"12","author":"Lopez","year":"2017","journal-title":"Epigenetics."},{"key":"10.1007\/s13311-021-01082-x_bib46","doi-asserted-by":"crossref","unstructured":"Germain ND, Chen PF, Plocik AM, Glatt-Deeley H, Brown J, Fink JJ, et al. Gene expression analysis of human induced pluripotent stem cell-derived neurons carrying copy number variants of chromosome 15q11-q13.1. Mol Autism. 2014;5:44.","DOI":"10.1186\/2040-2392-5-44"},{"key":"10.1007\/s13311-021-01082-x_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13229-018-0238-0","article-title":"Subcellular organization of UBE3A in human cerebral cortex","volume":"9","author":"Burette","year":"2018","journal-title":"Mol Autism."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35047554","article-title":"Genomic imprinting: parental influence on the genome","volume":"2","author":"Reik","year":"2001","journal-title":"Nat Rev Genet."},{"issue":"7","key":"10.1007\/s13311-021-01082-x_bib49","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/epi.15.70","article-title":"Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders","volume":"7","author":"LaSalle","year":"2015","journal-title":"Epigenomics."},{"issue":"7\u20138","key":"10.1007\/s13311-021-01082-x_bib50","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00018-007-6460-0","article-title":"Molecular epigenetics of Angelman syndrome","volume":"64","author":"Lalande","year":"2007","journal-title":"Cell Mol Life Sci."},{"issue":"11","key":"10.1007\/s13311-021-01082-x_bib51","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1093\/nar\/gkh670","article-title":"Regulation of the large (approximately 1000 kb) imprinted murine Ube3a antisense transcript by alternative exons upstream of Snurf\/Snrpn","volume":"32","author":"Landers","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"13","key":"10.1007\/s13311-021-01082-x_bib52","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1093\/hmg\/dds130","article-title":"Ube3a-ATS is an atypical RNA polymerase II transcript that represses the paternal expression of Ube3a","volume":"21","author":"Meng","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib53","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrg3594","article-title":"Gene regulation by antisense transcription","volume":"14","author":"Pelechano","year":"2013","journal-title":"Nat Rev Genet."},{"issue":"30","key":"10.1007\/s13311-021-01082-x_bib54","doi-asserted-by":"crossref","first-page":"9958","DOI":"10.1523\/JNEUROSCI.1728-10.2010","article-title":"Angelman syndrome, a genomic imprinting disorder of the brain","volume":"30","author":"Chamberlain","year":"2010","journal-title":"J Neurosci."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib55","doi-asserted-by":"crossref","first-page":"e1004039","DOI":"10.1371\/journal.pgen.1004039","article-title":"Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model","volume":"9","author":"Meng","year":"2013","journal-title":"PLoS Genet."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/mt.2015.236","article-title":"Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain","volume":"24","author":"Bailus","year":"2016","journal-title":"Mol Ther."},{"key":"10.1007\/s13311-021-01082-x_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-4939-7774-1_12","article-title":"Purified Protein Delivery to Activate an Epigenetically Silenced Allele in Mouse Brain","volume":"1767","author":"Pyles","year":"2018","journal-title":"Methods Mol Biol."},{"issue":"7539","key":"10.1007\/s13311-021-01082-x_bib58","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature."},{"issue":"8","key":"10.1007\/s13311-021-01082-x_bib59","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/ajmg.a.33509","article-title":"Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid","volume":"152A","author":"Peters","year":"2010","journal-title":"Am J Med Genet A."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib60","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/ajmg.a.34297","article-title":"A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome","volume":"155A","author":"Bird","year":"2011","journal-title":"Am J Med Genet A."},{"issue":"41","key":"10.1007\/s13311-021-01082-x_bib61","doi-asserted-by":"crossref","first-page":"17668","DOI":"10.1073\/pnas.1004487107","article-title":"Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes","volume":"107","author":"Chamberlain","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1007\/s13311-021-01082-x_bib62","doi-asserted-by":"crossref","first-page":"30792","DOI":"10.1038\/srep30792","article-title":"Angelman syndrome-derived neurons display late onset of paternal UBE3A silencing","volume":"6","author":"Stanurova","year":"2016","journal-title":"Sci Rep."},{"key":"10.1007\/s13311-021-01082-x_bib63","doi-asserted-by":"crossref","first-page":"15038","DOI":"10.1038\/ncomms15038","article-title":"Disrupted neuronal maturation in Angelman syndrome-derived induced pluripotent stem cells","volume":"8","author":"Fink","year":"2017","journal-title":"Nat Commun."},{"issue":"6","key":"10.1007\/s13311-021-01082-x_bib64","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1073\/pnas.1815279116","article-title":"A bipartite boundary element restricts UBE3A imprinting to mature neurons","volume":"116","author":"Hsiao","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"10.1007\/s13311-021-01082-x_bib65","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s003359900479","article-title":"A candidate model for Angelman syndrome in the mouse","volume":"8","author":"Cattanach","year":"1997","journal-title":"Mamm Genome."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/nbdi.2001.0463","article-title":"Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice","volume":"9","author":"Miura","year":"2002","journal-title":"Neurobiol Dis."},{"issue":"8","key":"10.1007\/s13311-021-01082-x_bib67","doi-asserted-by":"crossref","first-page":"e12278","DOI":"10.1371\/journal.pone.0012278","article-title":"Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3","volume":"5","author":"Jiang","year":"2010","journal-title":"PLoS One."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib68","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nn1845","article-title":"Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation","volume":"10","author":"van Woerden","year":"2007","journal-title":"Nat Neurosci."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib69","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nbd.2010.08.002","article-title":"Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome","volume":"40","author":"Mulherkar","year":"2010","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01082-x_bib70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2156-12-7","article-title":"Normal social seeking behavior, hypoactivity and reduced exploratory range in a mouse model of Angelman syndrome","volume":"12","author":"Allensworth","year":"2011","journal-title":"BMC Genet."},{"issue":"8","key":"10.1007\/s13311-021-01082-x_bib71","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/hmg\/ddr614","article-title":"Defective glucocorticoid hormone receptor signaling leads to increased stress and anxiety in a mouse model of Angelman syndrome","volume":"21","author":"Godavarthi","year":"2012","journal-title":"Hum Mol Genet."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib72","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1172\/JCI61888","article-title":"Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome","volume":"122","author":"Riday","year":"2012","journal-title":"J Clin Invest."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1523\/JNEUROSCI.2509-12.2013","article-title":"The Angelman syndrome protein Ube3a is required for polarized dendrite morphogenesis in pyramidal neurons","volume":"33","author":"Miao","year":"2013","journal-title":"J Neurosci."},{"issue":"6","key":"10.1007\/s13311-021-01082-x_bib74","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/jar.12462","article-title":"Identification of spatiotemporal gait parameters and pressure-related characteristics in children with Angelman syndrome: A pilot study","volume":"31","author":"Grieco","year":"2018","journal-title":"J Appl Res Intellect Disabil."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib75","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/hmg\/ddab104","article-title":"Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells","volume":"30","author":"Adhikari","year":"2021","journal-title":"Hum Mol Genet."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41398-020-0720-2","article-title":"Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome","volume":"10","author":"Berg","year":"2020","journal-title":"Transl Psychiatry."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13229-021-00416-y","article-title":"Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome","volume":"12","author":"Copping","year":"2021","journal-title":"Mol Autism."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib78","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/aur.2267","article-title":"Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion","volume":"13","author":"Dodge","year":"2020","journal-title":"Autism Res."},{"key":"10.1007\/s13311-021-01082-x_bib79","unstructured":"SP P, JD D, JL S. Gait as a Rigorous Translational Outcome Measure in Angelman Syndrome: Implications for Preclinical Models of Neurodevelopmental Disorders Autism Research. 2021 (In press)."},{"key":"10.1007\/s13311-021-01082-x_bib80","unstructured":"A S, SP P, JL S, JD D. Multiple Novel Measures of Motor Patterning Offer Insight into the Natural History of Angelman Syndrome Journal of Medical Genetics 2021 (In Press)."},{"issue":"7","key":"10.1007\/s13311-021-01082-x_bib81","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1523\/JNEUROSCI.23-07-02634.2003","article-title":"Derangements of hippocampal calcium\/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome","volume":"23","author":"Weeber","year":"2003","journal-title":"J Neurosci."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib82","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1038\/s41598-017-08825-x","article-title":"Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice","volume":"7","author":"Born","year":"2017","journal-title":"Sci Rep."},{"key":"10.1007\/s13311-021-01082-x_bib83","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2012.12.052","article-title":"Behavioral deficits in an Angelman syndrome model: effects of genetic background and age","volume":"243","author":"Huang","year":"2013","journal-title":"Behav Brain Res."},{"key":"10.1007\/s13311-021-01082-x_bib84","doi-asserted-by":"crossref","unstructured":"Copping and Silverman Molecular Autism (2021) 12:9. https:\/\/doi.org\/10.1186\/s13229-021-00416-y","DOI":"10.1186\/s13229-021-00416-y"},{"key":"10.1007\/s13311-021-01082-x_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s11689-017-9195-8","article-title":"Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis","volume":"9","author":"Sidorov","year":"2017","journal-title":"J Neurodev Disord."},{"issue":"9","key":"10.1007\/s13311-021-01082-x_bib86","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopsych.2019.01.008","article-title":"Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes","volume":"85","author":"Frohlich","year":"2019","journal-title":"Biol Psychiatry."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.seizure.2007.08.004","article-title":"Epilepsy in Angelman syndrome","volume":"17","author":"Pelc","year":"2008","journal-title":"Seizure."},{"key":"10.1007\/s13311-021-01082-x_bib88","doi-asserted-by":"crossref","unstructured":"Burette AC, Judson MC, Burette S, Phend KD, Philpot BD, Weinberg RJ. Subcellular organization of UBE3A in neurons. J Comp Neurol. 2016.","DOI":"10.1002\/cne.24143"},{"issue":"8","key":"10.1007\/s13311-021-01082-x_bib89","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/cne.23507","article-title":"Allelic specificity of Ube3a expression in the mouse brain during postnatal development","volume":"522","author":"Judson","year":"2014","journal-title":"J Comp Neurol."},{"key":"10.1007\/s13311-021-01082-x_bib90","doi-asserted-by":"crossref","first-page":"28238","DOI":"10.1038\/srep28238","article-title":"Persistent neuronal Ube3a expression in the suprachiasmatic nucleus of Angelman syndrome model mice","volume":"6","author":"Jones","year":"2016","journal-title":"Sci Rep."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/hmg\/ddm288","article-title":"The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology","volume":"17","author":"Dindot","year":"2008","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-021-01082-x_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5661\/bger-25-41","article-title":"Recent developments of biological reporter technology for detecting gene expression","volume":"25","author":"Jiang","year":"2008","journal-title":"Biotechnol Genet Eng Rev."},{"key":"10.1007\/s13311-021-01082-x_bib93","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev.biochem.67.1.509","article-title":"The green fluorescent protein","volume":"67","author":"Tsien","year":"1998","journal-title":"Annu Rev Biochem."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ng0195-3","article-title":"Of rats, mice, and men?","volume":"9","author":"Frankel","year":"1995","journal-title":"Nat Genet."},{"issue":"5939","key":"10.1007\/s13311-021-01082-x_bib95","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1126\/science.1172447","article-title":"Knockout rats via embryo microinjection of zinc-finger nucleases","volume":"325","author":"Geurts","year":"2009","journal-title":"Science."},{"issue":"7257","key":"10.1007\/s13311-021-01082-x_bib96","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/460788a","article-title":"Return of the rat","volume":"460","author":"Abbott","year":"2009","journal-title":"Nature."},{"issue":"7296","key":"10.1007\/s13311-021-01082-x_bib97","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/465282a","article-title":"Neuroscience: The rat pack","volume":"465","author":"Abbott","year":"2010","journal-title":"Nature."},{"issue":"10","key":"10.1007\/s13311-021-01082-x_bib98","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1242\/dmm.026120","article-title":"Rodent models in neuroscience research: is it a rat race?","volume":"9","author":"Ellenbroek","year":"2016","journal-title":"Dis Model Mech."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib99","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1152\/jn.00450.2011","article-title":"Molecular basis for the high THIP\/gaboxadol sensitivity of extrasynaptic GABA(A) receptors","volume":"106","author":"Meera","year":"2011","journal-title":"J Neurophysiol."},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01082-x_bib100","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.psyneuen.2009.08.010","article-title":"Function and modulation of delta-containing GABA(A) receptors","volume":"34","author":"Zheleznova","year":"2009","journal-title":"Psychoneuroendocrinology."},{"issue":"11","key":"10.1007\/s13311-021-01082-x_bib101","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI83541","article-title":"Dissociation of locomotor and cerebellar deficits in a murine Angelman syndrome model","volume":"125","author":"Bruinsma","year":"2015","journal-title":"J Clin Invest."},{"issue":"163","key":"10.1007\/s13311-021-01082-x_bib102","doi-asserted-by":"crossref","first-page":"163ra57","DOI":"10.1126\/scitranslmed.3004655","article-title":"Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome","volume":"4","author":"Egawa","year":"2012","journal-title":"Sci Transl Med."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib103","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.02.040","article-title":"GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility","volume":"90","author":"Judson","year":"2016","journal-title":"Neuron."},{"issue":"7","key":"10.1007\/s13311-021-01082-x_bib104","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1212\/WNL.0000000000011409","article-title":"The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome","volume":"96","author":"Bird","year":"2021","journal-title":"Neurology."},{"issue":"6","key":"10.1007\/s13311-021-01082-x_bib105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/14728222.2015.1010514","article-title":"The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders","volume":"19","author":"Guan","year":"2015","journal-title":"Expert Opin Ther Targets."},{"key":"10.1007\/s13311-021-01082-x_bib106","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuroscience.2016.03.056","article-title":"The role of Insulin-Like Growth Factor 1 (IGF-1) in brain development, maturation and neuroplasticity","volume":"325","author":"Dyer","year":"2016","journal-title":"Neuroscience."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib107","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1101\/lm.032375.113","article-title":"Activity-dependent changes in MAPK activation in the Angelman Syndrome mouse model","volume":"21","author":"Filonova","year":"2014","journal-title":"Learn Mem."},{"issue":"5","key":"10.1007\/s13311-021-01082-x_bib108","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2010.01.026","article-title":"The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc","volume":"140","author":"Greer","year":"2010","journal-title":"Cell."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib109","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1073\/pnas.1001281107","article-title":"Genomic imprinting of experience-dependent cortical plasticity by the ubiquitin ligase gene Ube3a","volume":"107","author":"Sato","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"10.1007\/s13311-021-01082-x_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nn.2327","article-title":"Ube3a is required for experience-dependent maturation of the neocortex","volume":"12","author":"Yashiro","year":"2009","journal-title":"Nat Neurosci."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib111","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbr.2010.02.039","article-title":"NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat","volume":"210","author":"Guan","year":"2010","journal-title":"Behav Brain Res."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib112","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/jcbfm.2009.109","article-title":"NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats","volume":"29","author":"Lu","year":"2009","journal-title":"J Cereb Blood Flow Metab."},{"key":"10.1007\/s13311-021-01082-x_bib113","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fnins.2016.00450","article-title":"Insulin-Like Growth Factor 1 and Related Compounds in the Treatment of Childhood-Onset Neurodevelopmental Disorders","volume":"10","author":"Vahdatpour","year":"2016","journal-title":"Front Neurosci."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2040-2392-4-9","article-title":"Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay","volume":"4","author":"Bozdagi","year":"2013","journal-title":"Mol Autism."},{"key":"10.1007\/s13311-021-01082-x_bib115","doi-asserted-by":"crossref","unstructured":"Cruz E, Descalzi G, Steinmetz A, Scharfman HE, Katzman A, Alberini CM. CIM6P\/IGF-2 Receptor Ligands Reverse Deficits in Angelman Syndrome Model Mice. Autism Res. 2020.","DOI":"10.1002\/aur.2418"},{"issue":"16","key":"10.1007\/s13311-021-01082-x_bib116","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","article-title":"Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome","volume":"92","author":"Glaze","year":"2019","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01082-x_bib117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2020.04.019","article-title":"A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome","volume":"110","author":"Berry-Kravis","year":"2020","journal-title":"Pediatr Neurol."},{"issue":"10","key":"10.1007\/s13311-021-01082-x_bib118","first-page":"499","article-title":"Lovastatin blocks N-ras oncogene-induced neuronal differentiation","volume":"1","author":"Mendola","year":"1990","journal-title":"Cell Growth Differ."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib119","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/BJ20060731","article-title":"Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts","volume":"401","author":"Cerezo-Guisado","year":"2007","journal-title":"Biochem J."},{"issue":"3","key":"10.1007\/s13311-021-01082-x_bib120","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1471-4159.2008.05458.x","article-title":"Lovastatin effect in rat neuroblasts of the CNS: inhibition of cap-dependent translation","volume":"106","author":"Santa-Catalina","year":"2008","journal-title":"J Neurochem."},{"key":"10.1007\/s13311-021-01082-x_bib121","doi-asserted-by":"crossref","unstructured":"Ottenhoff MJ, Krab LC, Elgersma Y. Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders. eNeuro. 2020;7(2).","DOI":"10.1523\/ENEURO.0392-19.2020"},{"issue":"21","key":"10.1007\/s13311-021-01082-x_bib122","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","article-title":"The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1","volume":"15","author":"Li","year":"2005","journal-title":"Curr Biol."},{"key":"10.1007\/s13311-021-01082-x_bib123","doi-asserted-by":"crossref","unstructured":"Muscas M, Louros SR, Osterweil EK. Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model. eNeuro. 2019;6(3).","DOI":"10.1523\/ENEURO.0097-19.2019"},{"key":"10.1007\/s13311-021-01082-x_bib124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2017.10.016","article-title":"Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model","volume":"110","author":"Chung","year":"2018","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01082-x_bib125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fnmol.2019.00289","article-title":"Simvastatin Restores HDAC1\/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse","volume":"12","author":"Kumar","year":"2019","journal-title":"Front Mol Neurosci."},{"issue":"24","key":"10.1007\/s13311-021-01082-x_bib126","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1212\/WNL.0000000000003435","article-title":"Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1","volume":"87","author":"Payne","year":"2016","journal-title":"Neurology."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib127","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s11689-020-09315-4","article-title":"Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome","volume":"12","author":"Thurman","year":"2020","journal-title":"J Neurodev Disord."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol."},{"issue":"8","key":"10.1007\/s13311-021-01082-x_bib129","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajmg.a.36023","article-title":"High MMP-9 activity levels in fragile X syndrome are lowered by minocycline","volume":"161A","author":"Dziembowska","year":"2013","journal-title":"Am J Med Genet A."},{"issue":"2","key":"10.1007\/s13311-021-01082-x_bib130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jmg.2008.061796","article-title":"Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model","volume":"46","author":"Bilousova","year":"2009","journal-title":"J Med Genet."},{"key":"10.1007\/s13311-021-01082-x_bib131","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12883-014-0232-x","article-title":"An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome","volume":"14","author":"Grieco","year":"2014","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib132","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13023-018-0891-6","article-title":"A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study)","volume":"13","author":"Ruiz-Antoran","year":"2018","journal-title":"Orphanet J Rare Dis."},{"key":"10.1007\/s13311-021-01082-x_bib133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13229-018-0231-7","article-title":"A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants","volume":"9","author":"Sonzogni","year":"2018","journal-title":"Mol Autism."},{"issue":"25","key":"10.1007\/s13311-021-01082-x_bib134","doi-asserted-by":"crossref","first-page":"12500","DOI":"10.1073\/pnas.1820131116","article-title":"UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology","volume":"116","author":"Wang","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6472","key":"10.1007\/s13311-021-01082-x_bib135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.aav5386","article-title":"Potassium channel dysfunction in human neuronal models of Angelman syndrome","volume":"366","author":"Sun","year":"2019","journal-title":"Science."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib136","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1038\/s41598-020-66790-4","article-title":"PKA and Ube3a regulate SK2 channel trafficking to promote synaptic plasticity in hippocampus: Implications for Angelman Syndrome","volume":"10","author":"Sun","year":"2020","journal-title":"Sci Rep."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib137","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1528-1167.2008.01888.x","article-title":"Anticonvulsant effects of the BK-channel antagonist paxilline","volume":"50","author":"Sheehan","year":"2009","journal-title":"Epilepsia."},{"issue":"17","key":"10.1007\/s13311-021-01082-x_bib138","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1093\/hmg\/ddu187","article-title":"Reactivation of maternal SNORD116 cluster via SETDB1 knockdown in Prader-Willi syndrome iPSCs","volume":"23","author":"Cruvinel","year":"2014","journal-title":"Hum Mol Genet."},{"issue":"7380","key":"10.1007\/s13311-021-01082-x_bib139","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature10726","article-title":"Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons","volume":"481","author":"Huang","year":"2011","journal-title":"Nature."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1517\/14740338.6.1.53","article-title":"Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer","volume":"6","author":"Garst","year":"2007","journal-title":"Expert Opin Drug Saf."},{"issue":"5","key":"10.1007\/s13311-021-01082-x_bib141","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-Approved Oligonucleotide Therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol Ther."},{"key":"10.1007\/s13311-021-01082-x_bib142","doi-asserted-by":"crossref","unstructured":"Schmid RS, Deng X, Panikker P, Msackyi M, Breton C, Wilson JM. CRISPR\/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice. J Clin Invest. 2021.","DOI":"10.1172\/JCI142574"},{"issue":"7833","key":"10.1007\/s13311-021-01082-x_bib143","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","article-title":"Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA","volume":"587","author":"Wolter","year":"2020","journal-title":"Nature."},{"issue":"12","key":"10.1007\/s13311-021-01082-x_bib144","doi-asserted-by":"crossref","first-page":"e27221","DOI":"10.1371\/journal.pone.0027221","article-title":"Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome","volume":"6","author":"Daily","year":"2011","journal-title":"PLoS One."},{"key":"10.1007\/s13311-021-01082-x_bib145","doi-asserted-by":"crossref","unstructured":"Born HA, Martinez LA, Levine AT, Harris SE, Mehra S, Lee WL, et al. Early Developmental EEG and Seizure Phenotypes in a Full Gene Deletion of Ubiquitin Protein Ligase E3A Rat Model of Angelman Syndrome. eNeuro. 2021;8(2).","DOI":"10.1523\/ENEURO.0345-20.2020"},{"key":"10.1007\/s13311-021-01082-x_bib146","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13229-018-0214-8","article-title":"Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study","volume":"9","author":"den Bakker","year":"2018","journal-title":"Mol Autism."},{"issue":"1","key":"10.1007\/s13311-021-01082-x_bib147","doi-asserted-by":"crossref","first-page":"niaa021","DOI":"10.1093\/nc\/niaa021","article-title":"Erratum: High-voltage, diffuse delta rhythms coincide with wakeful consciousness and complexity in Angelman syndrome","volume":"2020","author":"Frohlich","year":"2020","journal-title":"Neurosci Conscious."},{"issue":"9","key":"10.1007\/s13311-021-01082-x_bib148","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther."},{"issue":"7246","key":"10.1007\/s13311-021-01082-x_bib149","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nature07953","article-title":"Autism genome-wide copy number variation reveals ubiquitin and neuronal genes","volume":"459","author":"Glessner","year":"2009","journal-title":"Nature."},{"issue":"10","key":"10.1007\/s13311-021-01082-x_bib150","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/mp.2012.138","article-title":"Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts","volume":"18","author":"Moreno-De-Luca","year":"2013","journal-title":"Mol Psychiatry."},{"issue":"7304","key":"10.1007\/s13311-021-01082-x_bib151","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature09146","article-title":"Functional impact of global rare copy number variation in autism spectrum disorders","volume":"466","author":"Pinto","year":"2010","journal-title":"Nature."},{"key":"10.1007\/s13311-021-01082-x_bib152","unstructured":"Finucane BM, Lusk L, Arkilo D, Chamberlain S, Devinsky O, Dindot S, et al. 15q Duplication Syndrome and Related Disorders. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA)1993."},{"issue":"4","key":"10.1007\/s13311-021-01082-x_bib153","first-page":"928","article-title":"Autism or atypical autism in maternally but not paternally derived proximal 15q duplication","volume":"60","author":"Cook","year":"1997","journal-title":"Am J Hum Genet."},{"key":"10.1007\/s13311-021-01082-x_bib154","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-018-0191-y","article-title":"Significant transcriptional changes in 15q duplication but not Angelman syndrome deletion stem cell-derived neurons","volume":"9","author":"Urraca","year":"2018","journal-title":"Mol Autism."},{"key":"10.1007\/s13311-021-01082-x_bib155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13072-017-0134-4","article-title":"Genomic imprinting does not reduce the dosage of UBE3A in neurons","volume":"10","author":"Hillman","year":"2017","journal-title":"Epigenetics Chromatin."},{"issue":"5","key":"10.1007\/s13311-021-01082-x_bib156","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1172\/JCI80554","article-title":"Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model","volume":"125","author":"Silva-Santos","year":"2015","journal-title":"J Clin Invest."},{"key":"10.1007\/s13311-021-01082-x_bib157","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13229-019-0277-1","article-title":"Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes","volume":"10","author":"Sonzogni","year":"2019","journal-title":"Mol Autism."},{"key":"10.1007\/s13311-021-01082-x_bib158","doi-asserted-by":"crossref","unstructured":"Zylka MJ. Prenatal Treatment Path for Angelman Syndrome and Other Neurodevelopmental Disorders. Autism Res. 2019.","DOI":"10.1002\/aur.2203"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01082-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01082-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01082-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:54:33Z","timestamp":1761807273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":158,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1878747923007547"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01082-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01082-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}